Solid Lipid Nanoparticles: The Frontier in Drug Delivery (original) (raw)
Related papers
International Journal of Applied Pharmaceutics, 2019
Over the last few years, there has been a significant consideration of solid lipid nanoparticles (SLNs) as an alternative method to other colloidal dispersion methods for drug delivery. Special consideration has been given to the use of SLNs as a drug carrier in recent years. SLNs are aqueous dispersions in which the colloidal particles consist of solid lipids that are biodegradable. As a result of their physical stability, the protection of the entrapped drug from decomposition, the provision of controlled drug release, and the exceptional acceptability, SLNs have several advantages over other drug carriers. This article focuses on the techniques of SLNs preparation and characterization, the effect of formulation variables on SLNs properties, the routes of administration, and the pharmaceutical applications. The data used for this review was collected by searching on Google Scholar and PubMed using the following keywords during the period from 2010 to date.
Solid Lipid Nanoparticles-A Breakthrough In Novel Drug Delivery System
Solid lipid nanoparticles (SLNs) are the superseding drug delivery system in the nanotechnology sphere. SLNs has been developed at the beginning of 1990s with potential applications in the field of pharmaceuticals, cosmeceuticals, clinical medicine along with research as a substitute to the traditional colloidal carrier systems such as emulsions, liposomes since they exclude those downsides of the traditional system. SLN s offers a great way for controlled drug delivery and site targeting drug delivery as well. This article gives general information about the solid lipid nanoparticles, their production procedures and characterization. In addition to that, the recent advancements of drug delivery systems using SLNs were reviewed.
Research in Pharmaceutical Sciences, 2018
During the recent years, more attentions have been focused on lipid base drug delivery system to overcome some limitations of conventional formulations. Among these delivery systems solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are promising delivery systems due to the ease of manufacturing processes, scale up capability, biocompatibility, and also biodegradability of formulation constituents and many other advantages which could be related to specific route of administration or nature of the materials are to be loaded to these delivery systems. The aim of this article is to review the advantages and limitations of these delivery systems based on the route of administration and to emphasis the effectiveness of such formulations.
Nanotechnology is rapidly expanding research area, encompassing the development of man-made materials in nanometer size range. Nanoscale drug delivery system using various nanomaterials is emerging technology for the rational delivery of many chemotherapeutic agents. Nanoparticles attracted the scientists across many disciplines to engineer many desired properties that might otherwise be incompatible on a single device. Formulation scientists are facing the challenges such as poor solubility and bioavailability of the newly invented drugs. One of the approaches to face the above challenge is to develop the particulate carrier system. Solid lipid nanoparticle or liposphere or nanosphere system is the most feasible particulate carrier system which is an alternative to nanoemulsions, liposomes and polymeric nanoparticles. This system offers added advantages in comparison to other related particulate drug delivery systems. The present review emphasizes on various basic and applied aspects of solid lipid nanoparticles in novel drug delivery system especially techniques involved in their production, characterization and various applications. It also focuses on the drug loading capacity, drug incorporation and factors affecting drug release from this colloidal system.
A Systematic Review on Nano Drug Delivery System: Solid Lipid Nanoparticles (SLN)
International Journal of Current Pharmaceutical Research, 2024
Nanomedicine along with nano-delivery systems, are a young but fast-emerging science in which tiny materials are used as diagnostic tools or to deliver therapeutic drugs to specific targeted locations in a controlled manner. Nanotechnology has numerous advantages in the treatment of chronic human diseases through the site-specific and target-oriented delivery of precise medications. There have recently been several notable applications of nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents, and so on) in the treatment of various disorders. Efficient use of pricey medications and excipients, as well as cost savings in manufacturing Beneficial to patients, improved therapy, comfort, and the standard of living. Lipids have been proposed as an alternate carrier to circumvent the constraints of polymeric nanoparticles, notably for lipophilic medicines. Such small particles of lipid are known as solid lipid nanoparticles (SLNs), and they are gaining popularity among formulators all over the world. SLNs are colloidal carriers that were developed in the last decade as a replacement for traditional carriers. Lipid nanoparticles have caught the interest of researchers during the last two decades and have shown considerable therapeutic success since the first clinical approval of Doxil in 1995. Simultaneously, lipid nanoparticles have shown significant promise in conveying nucleic acid medications, as proven by the approval of two RNA treatments and an mRNA COVID-19 vaccination.
A SYSTEMATIC REVIEW ON NANO DRUG DELIVERY SYSTEM: SOLID LIPID NANOPARTICLES (SLN) Review Article
Nanomedicine along with nano-delivery systems, are a young but fast-emerging science in which tiny materials are used as diagnostic tools or to deliver therapeutic drugs to specific targeted locations in a controlled manner. Nanotechnology has numerous advantages in the treatment of chronic human diseases through the site-specific and target-oriented delivery of precise medications. There have recently been several notable applications of nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents, and so on) in the treatment of various disorders. Efficient use of pricey medications and excipients, as well as cost savings in manufacturing Beneficial to patients, improved therapy, comfort, and the standard of living. Lipids have been proposed as an alternate carrier to circumvent the constraints of polymeric nanoparticles, notably for lipophilic medicines. Such small particles of lipid are known as solid lipid nanoparticles (SLNs), and they are gaining popularity among formulators all over the world. SLNs are colloidal carriers that were developed in the last decade as a replacement for traditional carriers. Lipid nanoparticles have caught the interest of researchers during the last two decades and have shown considerable therapeutic success since the first clinical approval of Doxil in 1995. Simultaneously, lipid nanoparticles have shown significant promise in conveying nucleic acid medications, as proven by the approval of two RNA treatments and an mRNA COVID-19 vaccination.
Solid lipid nanoparticles (SLN) for controlled drug delivery
European Journal of Pharmaceutical Sciences, 1996
Solid lipid nanoparticles (SLN) introduced in 1991 represent an alternative carrier system to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro-and nanoparticles. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. This paper reviews the present state of the art regarding production techniques for SLN, drug incorporation, loading capacity and drug release, especially focusing on drug release mechanisms. Relevant issues for the introduction of SLN to the pharmaceutical market, such as status of excipients, toxicity/tolerability aspects and sterilization and long-term stability including industrial large scale production are also discussed. The potential of SLN to be exploited for the different administration routes is highlighted. References of the most relevant literature published by various research groups around the world are provided. q
SOLID LIPID NANOPARTICLES (SLNs) -AS NOVEL LIPID BASED NANOCARRIERS FOR DRUGS
2014
This review is focused on various aspects of Solid Lipid Nanoparticles (SLNs) as novel lipid based nanocarriers with size range between 10 to 1000 nm. SLNs were introduced to overcome problems of polymeric nanoparticles. By putting forward physiological safe lipids in place of polymers to prepare lipid nanoparticles, a novel formulation technique came into light. An approach undertaken here is to focus on various production methods for preparation of SLNs, and their suitability for large industrial scale. In addition, wide pharmaceutical applications of SLNs in drug delivery are explored. Diverse instrumental techniques have been highlighted to characterize the physiochemical properties of SLNs. Various routes of administration of SLNs as drug carriers are logistically reviewed and discussed. SLNs may open new vistas in therapy of complex diseases like cancer. This chapter also focuses on the merits of the SLNs over other colloidal drug carriers.
Applications of Solid Lipid Nanoparticle in Novel Drug Delivery System
British Biomedical Bulletin, 2013
Nanotechnology is rapidly expanding research area, encompassing the development of man-made materials in nanometer size range. Nanoscale drug delivery system using various nanomaterials is emerging technology for the rational delivery of many chemotherapeutic agents. Nanoparticles attracted the scientists across many disciplines to engineer many desired properties that might otherwise be incompatible on a single device. Formulation scientists are facing the challenges such as poor solubility and bioavailability of the newly invented drugs. One of the approaches to face the above challenge is to develop the particulate carrier system. Solid lipid nanoparticle or liposphere or nanosphere system is the most feasible particulate carrier system which is an alternative to nanoemulsions, liposomes and polymeric nanoparticles. This system offers added advantages in comparison to other related particulate drug delivery systems. The present review emphasizes on various basic and applied aspects of solid lipid nanoparticles in novel drug delivery system especially techniques involved in their production, characterization and various applications. It also focuses on the drug loading capacity, drug incorporation and factors affecting drug release from this colloidal system.
Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art
European Journal of Pharmaceutics and Biopharmaceutics, 2000
Solid lipid nanoparticles (SLN) introduced in 1991 represent an alternative carrier system to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro-and nanoparticles. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. This paper reviews the present state of the art regarding production techniques for SLN, drug incorporation, loading capacity and drug release, especially focusing on drug release mechanisms. Relevant issues for the introduction of SLN to the pharmaceutical market, such as status of excipients, toxicity/tolerability aspects and sterilization and long-term stability including industrial large scale production are also discussed. The potential of SLN to be exploited for the different administration routes is highlighted. References of the most relevant literature published by various research groups around the world are provided. q